Blood cancer Archives

onxeo cancer beleodaq interview Judith Greciet

News and Trends 22 Feb 2016

Meet the CEO of a Confident Orphan Oncology Biotech from France & Denmark

Last week, I was in Paris to meet with one of our Investors, during which time I also had a chance to visit the French Cancer Biotech, Onxeo. I met with the CEO of Onxeo, Judith Greciet, who was confident about the future of the company. She moved into the role in 2011 after having spent […]

February 22, 2016 - 4 minutesmins - By Philip Hemme

DIRK BUSCH TECHNICAL UNIVERSITY MUNICH car t leukemia all

News and Trends 17 Feb 2016

Cancer: World Best Ever CAR-T Results have Just been Disclosed

These are the best results yet for CAR-T, this time from a research group led by Dirk Busch at the Technical University of Munich (Germany). In part backed by Juno Therapeutics, a method to select more potent T-cells and engineer a safety mechanism was announced at the annual meeting of the AAAS in Washington (US). CAR-T therapies are one of the ways […]

February 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 12 Feb 2016

Biotech of the week: Nordic Nanovector & its ARC technology

This week we say ‘au revoir’ to Nantes and head back up to the Scandinavian country that is Norway, in particular it’s capital city, Oslo – the location of our biotech of the week, Nordic Nanovector. City: Oslo, Norway Founded: 2009 Employees: +/- 30 (as off 11/15) Financial Data: €156M Market Cap (on 23/11/2015) CEO: Missions: Betalutin, a potential new treatment […]

February 12, 2016 - 1 minutemin - By Philip Hemme

msd cancer research uk monash crt merck australia

News and Trends 1 Feb 2016

New Discovery unites Australia, Germany and UK Against Blood Cancers

Cancer Research UK has teamed up with MSD (Merck) and the Wellcome Trust to co-develop some Inhibitors for both Cancerous and Non-cancerous blood disorders from the Australian Academia-Biotech Network. The Australian Co-operative Research Centre (CRC) for Cancer Therapeutics (CTx) in Melbourne has a range of investigational inhibitors for blood disorders – including Leukemia. CTx is collaborative partnership […]

February 1, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 29 Jan 2016

Biotech of the week: Vivia Biotech, the Spanish Pioneer in Personalised Medicine

This week we leave the cold winds of Sweden and head south, to warmer weather and say ¡Hola! to Spain and the location for this week, Madrid. This vibrant city is famous for one of the best football teams in the world, the oldest restaurant in the world (opened in 1725!) and is home to the […]

January 29, 2016 - 2 minutesmins - By Philip Hemme

merck msd keytruda immunoncology lymphoma hodgkins affimed

News and Trends 26 Jan 2016

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

Affimed in Heidelberg (Germany) will fund and conduct a clinical trial to investigate the combination of Merck’s (MSD) anti-PD-1 therapy (Keytruda), with Affimed’s proprietary drug for the treatment of patients with Hodgkin lymphoma. The phase Ib trial will focus on patients whose disease has relapsed or is refractory to chemotherapy, including treatment with the marketed antibody-drug-conjugate […]

January 26, 2016 - 2 minutesmins - By Dani Bancroft

cancer biotech killers deadliest oncology therapies immunooncology

News and Trends 19 Jan 2016

Top 8 Deadliest Cancers and their Potential Cures

With more than 200 types of cancer, the possibility of developing a Universal Cure is in reality, a myth. However, the fight against the World’s Deadliest Cancers is far from being lost…and there lies hope in the Biotech Industry. Simply by having a quick look through our articles, we can easily confirm that cancer is […]

January 19, 2016 - 7 minutesmins - By Dani Bancroft

News and Trends 15 Jan 2016

Biotech of the week: Kiadis Pharma, Immuno-therapy made in Amsterdam

This week we say ‘auf Wiedersehen’ to Germany and head West to the Netherlands and it’s capital city, Amsterdam. This city really does have it all, whether you’re looking for history, architecture or something more indulgent… it is also the location of our biotech of the week: Kiadis Pharma City: Amsterdam, Netherlands Founded: 1997 Employees: 23 (as of 12/2015) […]

January 15, 2016 - 2 minutesmins - By Philip Hemme

cellectis ucart19 nature cancer car t cell leukemia crs cytokine

News and Trends 12 Jan 2016

Cellectis has Discovered an ‘On-Switch’ to Make CAR-T Safer and Better Controlled

Cellectis researchers have managed to come up with a new CAR architecture with a small-molecule triggered ‘on-switch’, permitting better control and safety in CAR T-cell therapy, as published in Nature. As we discussed during our interview with Andre Choulika, CEO of Cellectis, last month, one major drawback to CAR-T treatment for cancer is the lack of […]

January 12, 2016 - 3 minutesmins - By Dani Bancroft

merck msd cancer immunoncology complix alphabody

News and Trends 7 Jan 2016

Alphabody Platform for Cancer Draws in €260M Discovery Deal with MSD

Complix is a Belgian Immuno-Oncology Biotech with a proprietary Alphabody platform, which has now attracted a €260M strategic drug discovery collaboration with Merck Sharp & Dohme (MSD). Under the terms of the agreement, Complix will use its proprietary Alphabody platform to tackle two intra-cellular cancer targets. One example is the myeloid leukemia cell-1 protein (MCL-1), […]

January 7, 2016 - 2 minutesmins - By Dani Bancroft

leukemia ucart19 cellectis cancer cart trial UK

News and Trends 4 Jan 2016

Cellectis Full-Steam Ahead with UCART19 Trial for Leukemia in the UK

So it begins…dubbed the ‘Miracle Cure’ for Blood Cancer, UCART19 is now set to begin its journey to Human trials in the UK. Just 2 days before Christmas, the French billion euro Biotech, Cellectis, submitted a clinical trial application to the Medicines & Healthcare products Regulatory Agency (MHRA). Specifically, the request was to approve initiation […]

January 4, 2016 - 2 minutesmins - By Dani Bancroft

astrazeneca acerta pharma acquitision leukemia myeloma oncology cancer1

News and Trends 21 Dec 2015

Mystery Biotech No One has Ever Heard of in Biggest Deal of the Year for $7Bn

Acerta Pharma is an elusive Netherlands based Biotech with pipelines in Blood cancer and solid tumors which has somehow wrangled the biggest Biotech deal of 2015 with Pharma Giant AstraZeneca. Acerta Pharma is a Biotech start-up founded in 2012 which combines two technology platforms in drug discovery and development with a broad target range, from […]

December 21, 2015 - 3 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Blood cancer

Meet the CEO of a Confident Orphan Oncology Biotech from France & Denmark

Cancer: World Best Ever CAR-T Results have Just been Disclosed

Biotech of the week: Nordic Nanovector & its ARC technology

New Discovery unites Australia, Germany and UK Against Blood Cancers

Biotech of the week: Vivia Biotech, the Spanish Pioneer in Personalised Medicine

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

Top 8 Deadliest Cancers and their Potential Cures

Biotech of the week: Kiadis Pharma, Immuno-therapy made in Amsterdam

Cellectis has Discovered an ‘On-Switch’ to Make CAR-T Safer and Better Controlled

Alphabody Platform for Cancer Draws in €260M Discovery Deal with MSD

Cellectis Full-Steam Ahead with UCART19 Trial for Leukemia in the UK

Mystery Biotech No One has Ever Heard of in Biggest Deal of the Year for $7Bn

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!